| Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. | |
| | |
MedLine Citation:
|
PMID: 19881358 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND GOALS: Ursodeoxycholic acid (UDCA) is the only current pharmacologic treatment for primary biliary cirrhosis (PBC). However, some patients show persistent liver biochemical abnormalities even after 6 to 12 months treatment. Bezafibrate retard is a commonly used medication for hyperlipidemia. In Japanese studies, it was found to lower liver enzyme levels, apparently through its action on multiple drug resistance gene 3, a transport element of the ATP-dependent bile secretion system, and on peroxisome proliferator-activated receptor-alpha. The aim of this study was to evaluate the effect of adding bezafibrate to the treatment regimen in patients with PBC and a partial response to UDCA. STUDY: The study group included 8 White patients, 7 women and 1 man, aged 52 to 76 years with PBC who had been treated at our Liver Institute with UDCA (900 mg/d to 1500 mg/d) for 2 to 11 years (mean, 5.7 y) with only a partial response (19% to 56% reduction in alkaline phosphatase level). Bezafibrate (400 mg/d) was added to UDCA and the patients were followed for 4 to 12 months. RESULTS: Alkaline phosphatase levels (normal range, 35 to 104 U/L) decreased in all patients, from 140 to 360 U/L (mean, 201.2) to 68 to 158 U/L (mean, 98.4), and normalized in 6 patients. In addition, levels of gamma-glutamyl transferase (normal range, 6 to 42 U/L) decreased from 70 to 192 U/L (mean, 130) to 41 to 122 U/L (mean, 71.8). These findings were maintained throughout follow-up. CONCLUSIONS: Combination therapy with bezafibrate and UDCA improves the biochemical profile of patients with PBC who respond only partially to UDCA. A larger controlled study is needed to evaluate the clinical implications of these findings. |
| | |
Authors:
|
Rawi Hazzan; Ran Tur-Kaspa |
Related Documents
:
|
12644958 - The efficacy of flumazenil in subclinical to mild hepatic encephalopathic ambulatory pa... 21508068 - Transarterial chemoembolization and selective internal radiation for the treatment of p... 1584258 - Endoscopic biliary drainage for severe acute cholangitis. 16386568 - Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carc... 17645718 - Clinical trial on the cost-effectiveness of t-tube use in an established deceased donor... 12644958 - The efficacy of flumazenil in subclinical to mild hepatic encephalopathic ambulatory pa... |
Publication Detail:
|
Type: Controlled Clinical Trial; Journal Article |
Journal Detail:
|
Title: Journal of clinical gastroenterology Volume: 44 ISSN: 1539-2031 ISO Abbreviation: J. Clin. Gastroenterol. Publication Date: 2010 May-Jun |
Date Detail:
|
Created Date: 2010-04-21 Completed Date: 2010-08-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7910017 Medline TA: J Clin Gastroenterol Country: United States |
Other Details:
|
Languages: eng Pagination: 371-3 Citation Subset: IM |
Affiliation:
|
Department of Medicine D, Liver Institute, Rabin Medical Center Beilinson Hospital, Sackler School of Medicine Tel-Aviv University, Petah-Tikva, Israel. rawihazzan@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Alkaline Phosphatase / blood Antilipemic Agents / administration & dosage, therapeutic use* Bezafibrate / administration & dosage, therapeutic use* Cholagogues and Choleretics / administration & dosage, therapeutic use Drug Therapy, Combination Female Follow-Up Studies Humans Liver Cirrhosis, Biliary / drug therapy* Male Middle Aged Treatment Outcome Ursodeoxycholic Acid / administration & dosage, therapeutic use* gamma-Glutamyltransferase / blood |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Cholagogues and Choleretics; 128-13-2/Ursodeoxycholic Acid; 41859-67-0/Bezafibrate; EC 2.3.2.2/gamma-Glutamyltransferase; EC 3.1.3.1/Alkaline Phosphatase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: On the use of adjusted cross-sectional estimators of HIV incidence.
Next Document: Serum Apoptotic Caspase Activity in Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease.